By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > Markets > Stocks > Eli Lilly settles whistleblower lawsuit over manufacturing problems
Stocks

Eli Lilly settles whistleblower lawsuit over manufacturing problems

News Room
Last updated: 2023/09/29 at 1:55 PM
By News Room
Share
3 Min Read
SHARE

© Reuters. FILE PHOTO: Eli Lilly logo is shown on one of the company’s offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo

By Dan Levine and Marisa Taylor

(Reuters) – Eli Lilly (NYSE:) and Co and a former employee agreed to settle a lawsuit in which the worker claimed she was terminated after pointing out poor manufacturing practices and data falsification involving one of its blockbuster diabetes drugs, according to court filings.

The former human resources officer, Amrit Mula, contended in the lawsuit that she repeatedly urged leaders at a New Jersey plant to remedy problems involving several biologic drugs, including Type 2 diabetes medicine Trulicity.

Lilly called Mula a non-scientist whose allegations were “simply wrong,” according to court filings.

Both sides reached a tentative agreement this year and were working to finalize the settlement, according to an August court filing.

A judge set a Wednesday deadline to inform the court whether they would resume litigating, and said that if they did not, the case would be dismissed. Neither side made additional court filings.

A Lilly spokesperson said the resolution “in no way admits any wrongdoing,” and did not comment on details of the settlement. An attorney for Mula did not respond to an inquiry.

The New Jersey facility has been under scrutiny by the U.S. Food and Drug Administration since 2019 when inspectors found quality control data had been deleted and not appropriately audited, Reuters has reported. The plant has also produced several cancer medications and a COVID-19 therapy.

Inspectors later returned and found more problems, including that batches of drugs had been discarded because of manufacturing mistakes and quality control problems were not being properly investigated by the company to prevent recurrence.

Lilly has said it was working collaboratively with the FDA to address the agency’s concerns.

Separately, the U.S. Department of Justice in 2021 launched a criminal investigation following a Reuters story that detailed some of Mula’s allegations.

No charges have been filed. A DOJ spokesperson did not respond to a request for comment on the status of the investigation.

Read the full article here

News Room September 29, 2023 September 29, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Tesla reports weaker-than-expected Q3 profit, US stocks close lower

Watch full video on YouTube

How Zillow changed the way people buy, sell and rent homes

Watch full video on YouTube

Jamie Dimon signals support for Kevin Warsh in Fed chair race

Unlock the White House Watch newsletter for freeYour guide to what Trump’s…

Europe’s rocky relations with Donald Trump

Gideon talks to Jens Stoltenberg, Nato's former secretary-general, about Ukraine and Europe's…

Here’s why Tesla stock is moving lower after its Q3 earnings report. 🔻

Watch full video on YouTube

- Advertisement -
Ad imageAd image

You Might Also Like

Stocks

Playa Hotels & Resorts (NASDAQ:PLYA) Delivers Strong Q4 Numbers By Stock Story

By News Room
Stocks

ON24 (NYSE:ONTF) Posts Better-Than-Expected Sales In Q4 By Stock Story

By News Room
Stocks

Evolent Health shares leap on Q4 earnings beat and upbeat guidance By Investing.com

By News Room
Stocks

Chuy’s (NASDAQ:CHUY) Reports Q4 In Line With Expectations But Stock Drops

By News Room
Stocks

Red River Bancshares raises dividend to $0.09 per share

By News Room
Stocks

Ecolab appoints Microsoft executive to board

By News Room
Stocks

Semilux secures $50 million equity deal with White Lion Capital

By News Room
Stocks

US government debt trajectory to push long-term yields higher, says PIMCO

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?